MedTrace Logo

A Study of Flovent in Patients With Eosinophilic Esophagitis

NCT00426283 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2020-10-19

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to test the effects (both good and bad) of high dose swallowed fluticasone propionate (Flovent) in subjects with eosinophilic esophagitis (EoE).

Conditions

  • Eosinophilic Esophagitis

Interventions

DRUG

Flovent

1760 mcg daily

OTHER

Placebo

Placebo

Sponsors & Collaborators

  • Marc Rothenberg, MD

    lead OTHER

Principal Investigators

  • Marc E. Rothenberg, M.D., Ph.D. · Children's Hospital Medical Center, Cincinnati

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
3 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2011-12-31
Completion
2012-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00426283 on ClinicalTrials.gov